EMA rekommenderar godkännande för Trodelvy (sacituzumab govitecan) från Gilead för behandling av trippelnegativ bröstcancer

EMA has recommended granting a marketing authorisation in the European Union (EU) for Trodelvy (sacituzumab govitecan), a first-in-class medicine to treat adult patients with unresectable (cannot be removed by surgery) or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for advanced disease.

Läs hela utlåtandet